Fig. 2

Analysis of the TAG component of the lipid profile from blood plasma of individuals with lipodystrophy or insulin receptoropathies compared with matched controls. a O2PLS-DA analysis of the triglyceride dataset for the control (CON), lipodystrophic (LD) and insulin receptoropathy (INSR) groups (48 individuals in total; controls = 27, LD = 14, INSR = 7). One O2PLS-DA component and one orthogonal component are shown (R²(X) = 86.6%; R²(Y) = 33.5%; Q² = 26.3%; one O2PLS-DA component and five orthogonal components fitted). b O2PLS-DA analysis of the triglyceride dataset for the control and LD groups. One O2PLS-DA component and one orthogonal component are shown. (R²(X) = 77.8%; R²(Y) = 64.1%; Q² = 51.7%; one O2PLS-DA component and three orthogonal components fitted) c S-Plot of the O2-PLSDA analysis in (b) showing the most discriminatory TAG species for the separation. d Predicted class membership for the model in (b). In a perfect model control samples would score 1 and the LD samples score 0. e O2PLS-DA analysis of the triglyceride dataset for the LD and INSR groups. One O2PLS-DA component and one orthogonal component are shown. (R²(X) = 61.4%; R²(Y) = 63.4%; Q² = 57.0%; one O2PLS-DA component and one orthogonal component fitted). f The relative distribution of triglycerides across the different lipoprotein fractions in human plasma, based on size exclusion chromatography coupled to high resolution mass spectrometry using in-line automated liquid-liquid extraction. The cholersteryl ester CE(18:2) (666.618 m/z ± 5 ppm) shows the distribution of the different lipoprotein fractions. Smaller saturated triglycerides [TAG(46:1) (794.721 m/z ± 5 ppm), TAG(48:1) (822.752 m/z ± 5 ppm) and TAG(50:1) (850.785 m/z ± 5 ppm)] are specific for the VLDL fraction coming from the liver, while larger triglycerides [TAG(52:2) (876.800 m/z ± 5 ppm) and TAG(54:4) (900.800 m/z ± 5 ppm)] can also be found in the LDL fraction and therefore not only originating from the liver